Pfizer to Buy King Pharmaceutical
By wchung | 05 May, 2026
Pfizer Inc., the world’s largest pharmaceutical company by revenue, said Tuesday it will buy pain drug maker King Pharmaceuticals Inc. for $3.6 billion in cash.
Pfizer is paying $14.25 per share for King. That’s a premium of 40 percent to the stock’s Monday closing price of $10.15. Pfizer gains products including the pain drug Avinza, and Embeda, an extended-release pain treatment that is designed to be abuse-resistant.
King, of Bristol, Tenn., has struggled in recent years as patents on several of its key drugs have expired or been thrown out.
The boards of both companies approved the deal. Pfizer said the purchase will add about 2 cents per share to its profit in 2011 and 2012, and 3 to 4 cents per share in each of the next three years.
In premarket trading, King shares soared to $14.12, up 39 percent from Monday’s close. Pfizer shares dipped 8 cents to $17.30.
NEW YORK (AP)
Recent Articles
- Job Openings Fell in March but Hiring and Layoffs Surged
- Musk Wanted $80 Billion to Colonize Mars Testifies OpenAI President
- Nasdaq Hits Record on Surging AI Chip Stocks
- Anthropic's Deep Push into Finance Tasks Likely to Disrupt Software Sector
- 'Yaris Moment' in the Works for Chinese Carmakers Chasing Overseas Growth
- Volvo's Q1 Full-EV Sales Rose 14% in Challenging Market
- Hong Kong Q1 GDP Expanded Fastest in Nearly Five Years
- Hugo Boss Beats on Profit Despite Iran
- PayPal Q1 Beats on Top Line on Spending by Affluent Consumers
- Coinbase Cuts Workforce on Crypto Market Volatility